SerpApi.Org
Life sciences company Repligen Corporation RGEN on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. BLFS for an enterprise value of approximately $1.5 billion.
Repligen Expands Into Cell Therapy
The acquisition aims to capitalize on the rapidly expanding cell therapy sector. Industry commercial revenues are forecast to surge by over 20% annually through 2030.
BioLife’s biopreservation products, notably CryoStor, complement Repligen’s existing bioprocessing technologies.
Currently, BioLife’s portfolio supports 18 commercialized therapies and a majority of United States cell-based clinical trials.
The merger allows BioLife to leverage Repligen’s extensive international footprint, particularly in the Asia Pacific region, while providing the company access to an established customer base.
Financial Synergies And Deal Terms
BioLife shareholders will receive $11.25 in cash and 0.1442 Repligen shares for each BioLife share they own. The combined consideration is valued at about $31.00 per share.
This represents a 24% premium based on the 90-day volume-weighted average price as of July 21, 2026. The company expects the purchase to immediately boost revenue growth and adjusted margins.
The company projects an adjusted earnings per share increase of at least 5 cents in the first year, escalating to at least 25 cents in the second year.
Repligen expects to generate at least $20 million in cost savings initially. Those savings are projected to increase to at least $30 million the following year.
With over $300 million in projected cash reserves, Repligen maintains a robust balance sheet for additional M&A and other investment opportunities.
Repligen reported $785 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Preliminary Second Quarter Results
Ahead of the finalized deal, both companies reported preliminary second-quarter performance compared to 2025. Repligen expects organic revenue growth of 13% and robust margin expansion. Meanwhile, BioLife projects a 21% revenue jump to $28.5 million.
William Blair called the acquisition “a great fit” for Repligen, saying the deal “checks a lot of the key boxes needed for a successful” acquisition. Analyst Matt Larew added that the firm continues to view Repligen as “a best-in-class bioprocessing pure-play” and maintains an Outperform rating on the stock.
Repligen, BioLife Stock Price Activity
RGEN/BLFS Stock Price Activity: Repligen shares were down 3.10% at $132.75, and BioLife Solutions shares were up 2.77% at $30.00 during premarket trading on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
This article Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition originally appeared on Benzinga.com.
